Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.1552W HIGH $8.77
Volume
525.25 K
Value Traded
9.79 M
Short % Float
12.09%
Days to Cover
7.4
-9.12%Week
-12.54%1 Month
-28.83%3 Month
-11.71%6 Month
-94.45%5 Year
-83.45%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
131.95 M
EPS (TTM)
-2.60
P/E Ratio
-
Ent. Value
38.42 M
Total Shares
47.27 M
Float Shares
41.75 M
Insiders
11.73%
Institutions
62.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
QTRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Quanterix Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Quanterix Corporation
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How QTRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Quanterix Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every QTRX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Miller Michael FrancisOfficer (Chief Technology Officer) | Option | 81 38,533 held | $0.00 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in QTRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.1 % (-50 %) | 1.20 M | 341.45 K | 3.8% ( 12.50 K) |
QTRX Institutional Ownership Trends
QTRX Short Interest
Shares sold short, counted twice a month.
12.09%
Short % of Float
of tradable shares sold short
5.0M
Shares Sold Short
+1.4% vs prior count
7.4 High
Days to Cover
trading days of normal volume to buy every short share back
679.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How QTRX ranks across every disease it competes in
Competitive Position is a premium feature
See how QTRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialQTRX News
QTRXALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research
ALZpath has expanded its licensing agreement with Quanterix to enhance Alzheimer's disease biomarker research using the pTau217 antibody technology. This agreement builds on a previous collaboration and aims to improve blood-based diagnostic tools for Alzheimer's. The pTau217 assay has been instrumental in numerous studies, indicating its significance in understanding the disease.
Read more →QTRXQuanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
Quanterix Corporation and Innovita Biological Technology have received regulatory approvals from China's National Medical Products Administration. This partnership aims to enhance access to Quanterix's SIMOA technology and neurology biomarker testing in the Chinese market. The collaboration is expected to significantly improve diagnostic capabilities in the region.
Read more →QTRXQuanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
Quanterix Corporation has announced notable advancements in its Content Innovation Engine, initially introduced at the AACR Annual Meeting 2026. These updates were presented at the European Society for Spatial Biology (ESSB) event, reflecting the company's commitment to providing essential assays for researchers in the field of spatial biology.
Read more →QTRX▲ +7.2%on this news
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation announced inducement grants for its new Chief Commercial Officer, James Gute, and two other employees. The grants, made on September 15, 2026, include 260,315 restricted stock units for Mr. Gute. This move is part of the company's strategy to attract and retain top talent in the biomarker science field.
Read more →QTRXQuanterix Names Dr. Yuri Fesko Chief Medical Officer
Quanterix Corporation has appointed Dr. Yuri Fesko as Chief Medical Officer. In this role, Dr. Fesko will lead medical and clinical initiatives, collaborating with various teams including Diagnostics and R&D. His expertise is anticipated to drive advancements in the company's innovative technologies.
Read more →QTRX▼ -40%on this news
Quanterix Names Jim Gute Chief Commercial Officer
Quanterix Corporation has appointed Jim Gute as Chief Commercial Officer. Gute, a seasoned healthcare executive, will oversee the company's commercial operations and drive growth, particularly in diagnostics. The leadership change comes at a crucial time as Quanterix aims to expand its market presence.
Read more →QTRX▼ -40%on this newsshared move
Quanterix Releases Financial Results for the Second Quarter of 2026
Quanterix Corporation reported its financial results for Q2 2026, highlighting progress in leadership and cash management. However, the company faced challenges as revenue did not meet expectations due to execution issues and ongoing market softness. Immediate actions are being taken to address these challenges.
Read more →QTRXQuanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
Quanterix Corporation will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12, 2026. CEO Everett Cunningham is scheduled to engage in a live webcast fireside chat on August 12th, where he will discuss updates regarding the company's progress in precision biomarker science. This participation highlights Quanterix's commitment to transparency and engagement with investors.
Read more →QTRXQuanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
Quanterix Corporation has announced a conference call scheduled for August 10, 2026, to discuss its financial results for the second quarter of 2026. Prior to this call, a press release detailing the financial results will be made available on the company's website. This event reflects the company's commitment to keeping investors informed.
Read more →QTRXQuanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation has announced an inducement grant in accordance with Nasdaq Listing Rule 5635(c)(4). This action demonstrates the company's ongoing commitment to adhere to regulatory standards while potentially enhancing its attractiveness to investors.
Read more →QTRXAnthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
Quanterix Corporation announced significant milestones in the clinical adoption of its blood-based Alzheimer's testing, LucentAD® Complete. Anthem Blue Cross and Blue Shield has established commercial coverage for this innovative five-analyte ATN(I) algorithmic test, which aids clinicians in evaluating Alzheimer's disease. These developments highlight the increasing importance of blood-based assessments in Alzheimer's diagnostics.
Read more →QTRXQuanterix Announces Appointment of Jason Faessler as Chief Financial Officer
Quanterix has announced the appointment of Jason Faessler as Chief Financial Officer. This leadership change is part of the company's strategy to enhance its financial management. Further details about Faessler's background and the implications of this appointment were not provided.
Read more →QTRXQuanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Quanterix is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Details regarding the specific agenda or topics to be discussed at the conference have not been provided in the article. This participation highlights Quanterix's ongoing engagement in the healthcare sector.
Read more →QTRXQuanterix Announces Planned Transition of Chief Financial Officer
Quanterix has announced a planned transition for its Chief Financial Officer. The details regarding the timing and the successor have not been disclosed in the announcement. This change is part of the company's ongoing leadership adjustments. Further information may be provided in upcoming communications.
Read more →QTRXLucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows
Lucent Diagnostics has partnered with Tempus AI to enhance Alzheimer's disease detection through a blood-based biomarker panel. This collaboration aims to integrate the testing into clinical workflows, leveraging AI technology to improve precision medicine. The initiative is expected to broaden access to this novel testing method, potentially benefiting early diagnosis and treatment.
Read more →QTRXQuanterix Releases Financial Results for the First Quarter of 2026
Quanterix has released its financial results for the first quarter of 2026. The article does not provide specific details regarding the financial performance or any significant developments. Further insights into the company's financial health and future outlook are not available in the provided text.
Read more →QTRXQuanterix To Report First Quarter 2026 Financial Results on May 6, 2026
Quanterix Corporation announced it will report its first quarter 2026 financial results on May 6, 2026. A conference call will be held at 4:30 p.m. E.T. to discuss these results. The company will issue a press release before the call and provide a live webcast for interested investors.
Read more →QTRXAidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
The article discusses the AidaBREAST™ multi-omic assay, which is designed for clinical oncology. However, it provides minimal information about the assay's performance or results. The content is primarily focused on privacy concerns, limiting the insights available to readers. Overall, the article does not convey significant positive developments regarding the assay.
Read more →About Quanterix Corporation
Headquarters900 MIDDLESEX TURNPIKE, BILLERICA, MA, 01821
BIOPHARMAWATCH ELITE PLUS
Trade the next QTRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime